Manuel Monreal: DOACs Show Advantages Over VKAs in DVT Patients
Manuel Monreal, Coordinator of the RIETE Registry, shared a post on X about a recent article he and his colleagues co-authored, published in The European Journal of Internal Medicine, adding:
“Among DVT patients with similar eligibility for the pivotal RCTs, DOACs were associated with lower risks of recurrent VTE and major bleeding.
But no significant reduction was observed in trial-ineligible patients (around 15 percent of the total).”
Title: Recurrent venous thromboembolism and bleeding during anticoagulation in patients with deep-vein thrombosis treated with vitamin K antagonists or direct oral anticoagulants: insights from the RIETE registry
Authors: Paolo Prandoni, Raffaele Pesavento, Franca Bilora, Benjamin Brenner, Iria Francisco, Germán Sierra-Palomares, Ángeles Fidalgo, Jana Hirmerova, Samuel Fonseca, Manuel Monreal
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 18, 2026, 17:11Owen McCarty: Understanding Prekallikrein and Its Role in Inflammation and Thrombosis
-
Oct 18, 2026, 17:04Emna Gouider Belhadjali: Don’t Miss GPAS 2026 on Bleeding Disorders
-
Oct 18, 2026, 16:53Mehran Ghasemzadeh: Microparticle-Associated Mitochondrial DNA in Stored Platelet Products
-
Oct 18, 2026, 16:38Edward Lee Carter: A 15-Minute Blood Test for Brain Hemorrhage?
-
Oct 18, 2026, 16:29Patrick Taylor: Oral vs Transdermal Estrogen and Cardiovascular Risk in Menopausal Women
-
Oct 18, 2026, 16:19Artangela Henry: A Meaningful Week at the SCDAA National Convention
-
Oct 18, 2026, 16:04Emília Araújo։ New Insights Into the Genetics of Hemophilia B Leyden
-
Oct 18, 2026, 15:43André Marcel Harris: Award-Winning Research on Texas Sickle Cell Data Collection
-
Oct 18, 2026, 15:21Eleonora Gambineri: First Results of the IEI-Haem Consortium at ESID 2026